NCT02991742

Ioxaglate Versus Iodixanol for the Prevention of Contrast-induced Nephropathy in High-risk Patients (IDPC Trial)

Ioxaglate Versus Iodixanol for the Prevention of Contrast-induced Nephropathy in High-risk Patients After Diagnostic and Therapeutic Cardiac Catheterization (IDPC Trial)

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 2,262 (estimated)
• Sponsor: Instituto Dante Pazzanese de Cardiologia · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Contrast media-induced nephropathy following diagnostic and therapeutic cardiac catheterization.

Detailed description

Contrast-induced acute kidney injury represents a serious complication of procedures requiring administration of iodinated contrast media and is associated with the need for dialysis, prolonged hospitalization, increased costs, and mortality. Contrast-induced nephropathy is defined as an increase of 25% in serum creatinine before the procedure. Iodixanol, a nonionic, dimeric, iso-osmolar contrast medium may be less nephrotoxic than low-osmolar contrast media in high-risk patients. The purpose of this study is to compare iodixanol versus ioxaglate in high risk patients between 48 and 96 hours after procedures that use contrast.

Conditions

• Acute Kidney Failure

Interventions

Type	Name	Description
OTHER	contrast media	Compare 2 contrast media

Timeline

• Start date: 2016-12-01
• Primary completion: 2016-12-01
• Completion: 2020-11-01
• First posted: 2016-12-13
• Last updated: 2016-12-14